Alzheimer's disease recognition based on waveform and spectral speech signal processing
View abstract on PubMed
Summary
This summary is machine-generated.Speech analysis offers a new way to detect Alzheimer's disease (AD). A novel AD recognition network (ADNet) analyzes speech features, showing promise for early AD detection and distinguishing it from normal cognition.
Area Of Science
- Neuroscience
- Computational Linguistics
- Medical Informatics
Background
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Current AD diagnosis relies on invasive and expensive methods.
- Early detection of AD is crucial for effective management.
Purpose Of The Study
- To propose a novel multi-channel network framework (ADNet) for Alzheimer's disease recognition using speech analysis.
- To investigate the efficacy of integrating time-domain and frequency-domain speech features for AD detection.
Main Methods
- Developed ADNet, a multi-channel network integrating time-domain and frequency-domain speech features.
- Utilized waveform images and log-Mel spectrograms as speech signal data sources.
- Employed inverted residual blocks and gated multi-information units for feature learning and integration.
Main Results
- The proposed ADNet achieved high performance on the Shanghai Cognitive Screening (SCS) dataset.
- Achieved an accuracy of 88.57%, precision of 88.67%, and recall of 88.64%.
- Outperformed existing speech-based methods for Alzheimer's disease recognition.
Conclusions
- The ADNet framework effectively distinguishes Alzheimer's disease patients from healthy controls.
- Speech analysis, particularly using the proposed ADNet, shows significant potential for early AD recognition tools.
- This approach offers a non-invasive and potentially cost-effective method for AD screening.
Related Concept Videos
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
Brain waves are electrical signals generated by the neurons in the brain, which are regularly monitored to measure mental activities. Brain waves and their frequency ranges can be measured using an electroencephalogram or EEG. There are four main types of brain waves, each with distinct characteristics:
• Alpha Waves – Alpha brain waves, between 8 and 13 Hz ( Hertz), occur when a person is relaxed with eyes closed. The alpha waves then disappear when one is concentrating on...

